Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1154

—

90bf15f6-975f-5207-9c66-40fc73db59df

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • COAGULATION+0.360
  • KRAS_SIGNALING_DN+0.359
  • ANGIOGENESIS+0.337
  • PANCREAS_BETA_CELLS+0.319
  • MYOGENESIS+0.285
  • APICAL_SURFACE+0.254
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.246
  • KRAS_SIGNALING_UP+0.225
  • APICAL_JUNCTION+0.185
  • ESTROGEN_RESPONSE_LATE+0.167

Top 10 suppressed

  • PROTEIN_SECRETION-0.534
  • TGF_BETA_SIGNALING-0.507
  • UNFOLDED_PROTEIN_RESPONSE-0.494
  • MYC_TARGETS_V1-0.479
  • UV_RESPONSE_DN-0.444
  • MITOTIC_SPINDLE-0.413
  • ANDROGEN_RESPONSE-0.396
  • G2M_CHECKPOINT-0.394
  • INTERFERON_ALPHA_RESPONSE-0.393
  • MTORC1_SIGNALING-0.391

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

0 twins match this tumor's tissue · 10 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SRR1387032
brain-umap@2
GTEX—0.913
2SRR1448226
brain-umap@2
GTEX—0.912
3BS_PQ7CQFYR
brain-umap@2
Ganglioglioma—0.910
4SRR1488651
brain-umap@2
GTEX—0.909
5SJEPD001523_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.908
6SRR1340301
brain-umap@2
GTEX—0.906
7SRR1316624
brain-umap@2
GTEX—0.904
8SRR1459423
brain-umap@2
GTEX—0.903
9MDT-AP-0225
medullo-epn-umap@date-based
MedMedulloblastoma0.900
10SRR1457551
brain-umap@2
GTEX—0.899

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
COAGULATION0.360Binimetinib— uncovered
KRAS_SIGNALING_DN0.359Remibrutinib— uncovered
ANGIOGENESIS0.337Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.319Cobimetinib— uncovered
MYOGENESIS0.285Inavolisib— uncovered
APICAL_SURFACE0.254Temsirolimus— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.246Inavolisib— uncovered
KRAS_SIGNALING_UP0.225Inavolisib— uncovered
APICAL_JUNCTION0.185Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.167Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.146Idelalisib— uncovered
COMPLEMENT0.093Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.083Inavolisib— uncovered
ALLOGRAFT_REJECTION0.081Idelalisib— uncovered
SPERMATOGENESIS0.079Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.070Inavolisib— uncovered
P53_PATHWAY0.039Idelalisib— uncovered
BILE_ACID_METABOLISM0.011Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.010Inavolisib— uncovered